Review on Phenoxybenzamine for Veterinary Use

Abstract

In veterinary medicine, phenoxybenzamine, a non-selective irreversible alpha-adrenergic antagonist, is frequently employed because of its capacity to relax smooth muscles in the urinary system and blood vessels. This medication works well for treating diseases like urethral blockage in dogs and cats caused by functional urethrospasm. [1]It also inhibits alpha-adrenergic-mediated vasoconstriction, which is used to manage hypertension in cases of pheochrocytoma, a catecholamine-secreating tumor. Because of its lengthy half-life, phenoxybenzamine is a good option for long-term treatment of several disorders. However, due to the possibility of adverse effects such tachycardia, hypotension, and gastrointestinal disturbance, careful dose and monitoring are required. It is a useful treatment alternative in veterinary medicine because of its effectiveness in reducing urine retention and regulating blood pressure in emergency conditions, even with these possible adverse effects. It is advised that more research be done to improve dosage guidelines and expand clinical use.[2].

Keywords

Introduction

The non-selective alpha adrenoreceptor antagonist phenoxybenzamine (POB) forms an irreversible, covalent bond with its target receptors. within the past few years. As an antispasmodic, POB has been used to reduce adrenergic-mediated radial artery vasoconstriction. Additionally, POB is authorized to treat pheochromocytoma-related hypertension and diaphoresis. POB has several uses in veterinary medicine, including treating severe nonresponsive diarrhea in horses, managing urinary tract disease in cats, and lowering blood pressure and maximal urethral pressure in dogs. Pretreatment with phenoxybenzamine is also inhibited_.[3]

Ideal Characteristics of Phenoxybenzamine

1.Efficacy

Alpha-blockers: Phenoxybenzamine is a non-selective, irreversible alpha-adrenergic antagonist. Its primarily active ingredient acts on alpha-1 and alpha-2 adrenergic receptors, which in turn causes vasodilation with a corresponding decrease in smooth muscle tone; this effect may be used in animals in relation to pheochromocytoma or hypertensive crises.

Action duration: Drug effectiveness must be timed to give minimal, varied intervals in symptom control between doses, and any irreversible binding of the drug on receptors should ensure for prolonged effects that tend to be advantageous in management of diseases during which a continuous follow-up treatment is required.

Effect on blood pressure: The ability of the drug to reduce systemic vascular resistance and blood pressure is important, particularly in cases of hypertension arising from underlying conditions such as pheochromocytoma or other causes of increased adrenergic activity.

2.Safety Profile

Few adverse effects at the lower dose: It is suspected that this product formulation for veterinary purposes has such a safety profile that hypotension, tachycardia, and other reflex effects caused by vasodilation are encountered infrequently; this is especially important as many target animals are already adversely affected by underlying disease.

Tolerability: The drug should dodge most major side effects, such as sedation, dizziness, or nausea, so that it may be given to a wide variety of animal species. Renal and hepatic clearance: It is important that phenoxybenzamine is adequately metabolized and eliminated, preferably with minimal hepatic or renal burden, particularly in animals with pre-existing liver or kidney conditions.

3.Targeted Use in Specific Conditions

Pheochromocytoma: The management of pheochromocytoma symptoms (adrenal tumors producing high levels of catecholamines) involves use of phenoxybenzamine. In this respect, the ideal product formulation would provide relief from catecholamine-induced hypertension and enhanced quality of life through the mitigation of symptoms like tachycardia, arrhythmias, and hypertension.

4.Minimal Drug Interactions

Compatibility with Other Medications: The ideal formulation of phenoxybenzamine should not interact negatively with commonly used veterinary drugs, such as anesthetics, corticosteroids, or other antihypertensives.

Clear Dosage Guidelines: Given the variability in pharmacokinetics across species, the ideal product would have clear and species-specific dosing guidelines to avoid complications.

5. Species-Specific Formulations

Adjustable Dosing for Different Animals: The ideal formulation would cater to different species, with specific recommendations for common veterinary patients (e.g., dogs, cats, horses). This is important because different animals may have different sensitivities to the drug.

Ease of Administration: Phenoxybenzamine should come in an easily administrable form, whether as oral tablets, injectable formulations, or liquid preparations. For some species, palatability and ease of dosing are particularly important.

6. Minimized Risk of Severe Adverse Effects

Hypotension Management: Since phenoxybenzamine can lower blood pressure, its use should be monitored carefully to avoid causing too profound hypotension or shock. The ideal product would allow for easy dose adjustments and clinical monitoring.

Monitoring Parameters: Veterinary use would benefit from clear guidelines on what to monitor during treatment, including blood pressure, heart rate, and overall fluid balance._{[4]  [5]  [6]}

Mechanism Of Action of Phenoxybenzamine

Alpha1receptor-blockade
Vasodilation: Phenoxybenzamine prevents vasoconstriction normally seen when catecholamines (norepinephrine) activate the alpha-1 receptor responsible for vasodilation which eventually lowers blood pressure.Reduction in peripheral vascular resistance: As a result, afterload on the heart drops in conditions suitable such as hypertension Alpha-1 Receptor Blockade

Alpha-2Receptor-Blockade
Increased release of norepinephrine: By antagonizing the presynaptic alpha-2 norepinephrine receptor phenoxybenzamine increases norepinephrine levels abundant at the nerve terminals. While such a view may seem paradoxical, the net outcome remains a decrease in arterial blood pressure mainly because vasodilation is greatly increased by alpha-1 receptor antagonism

Vasodilation and Low Blood Pressure:

The blockade of alpha-1 receptors by phenoxybenzamine prevents vasoconstriction and leads to vasodilation, which causes low blood pressure. This is particularly useful in conditions like pheochromocytoma, where excessive catecholamines, such as norepinephrine, cause excessive vasoconstriction and hypertension._{[7] [8]}

Specific Animal Responses:
Rats and mice: These animals are commonly utilized in experimental studies to evaluate the pharmacological activities of phenoxybenzamine. They may display obvious tachycardia, hypotension, and enhanced blood flow in the peripheral tissues.
Dogs: In veterinary clinical use, dogs are administered phenoxybenzamine for pheochromocytoma and other conditions.

They would also present with hypotension and compensatory tachycardia. This might lead to a likelihood  of postural hypotension, especially when assuming an upright posture.
Primates:henoxybenzamine may produce less pronounced alterations in blood pressure regulation and sympathetic tone, but the overall effects (hypotension and tachycardia) are similar to other species._{[9] [10]}
Side Effects

1.Hypotension
Phenoxybenzamine can cause a lowering of blood pressure, with signs of hypotension including weakness, dizziness, lethargy, or fainting. This is particularly problematic if the drug is used in higher doses or in patients with pre-existing cardiovascular disease.

2. Tachycardia (Rapid Heart Rate)
As the blood pressure drops, the heart rate of the animal may increase as a compensatory mechanism. This could potentially cause palpitations or arrhythmias, especially in animals with heart

3.Gastrointestinal (GI) upset:

 Animals may become nauseated, vomit, or have diarrhea from the action of the drug on smooth muscle and the autonomic nervous system._[11]

Pharmacokinetics;

Phenoxybenzamine is an alpha-adrenergic antagonist that is often utilized in veterinary medicine to counteract conditions such as pheochromocytoma, urinary retention, and some forms of hypertension. Its pharmacokinetics may vary with species, but generally, the characteristics of the drug are described below.

Absorption:

 Phenoxybenzamine, when administered orally, is adequately absorbed from the gastrointestinal tract. However, there is considerable first-pass metabolism of the drug by the liver, which decreases its bioavailability.

Distribution:

 Phenoxybenzamine is widely distributed in the body with a high affinity for plasma proteins, which affects the distribution and availability of this drug to target tissues.

Metabolism:

 It is mainly metabolized in the liver. The metabolites of phenoxybenzamine are excreted through urine. Its metabolism may be affected by liver function, and care must be taken in animals with hepatic impairment.

Elimination

The drug has a relatively long half-life, which explains the maintenance of its effects after taking one dose. It is mainly removed from the body through the excretion process of the kidneys, with some components being further._{[12] [13]}

Interactions:

Potential Drug Interactions

Alpha-adrenergic Agonists (e.g., epinephrine, norepinephrine)

Interaction: Since phenoxybenzamine is an alpha blocker, it blocks alpha receptors, which means the effects of alpha-agonist drugs such as epinephrine and norepinephrine could be reduced or even canceled out.

Clinical Implication: If alpha-agonist drugs are given together with phenoxybenzamine, it could inhibit the drugs, which are used in emergency settings to raise blood pressure or in treating anaphylaxis.

Beta-adrenergic Agonists (e.g., isoproterenol)

Interaction: The combination of an alpha-blocker like phenoxybenzamine with a beta-agonist causes a more important decrease in blood pressure due to unopposed beta-adrenergic activity, primarily causing vasodilation and heart rate increase.

Clinical Significance: This will cause severe hypotension and must be monitored when used together.

Other Antihypertensive Drugs

Interaction: The blood pressure-lowering effects of the combination with other antihypertensive drugs, like ACE inhibitors, calcium channel blockers, or diuretics may be additive. Clinical Importance: This may cause hypotension. Therefore, the blood pressure needs to be monitored carefully during therapy.

Anesthetics Isoflurane Sevoflurane Interaction: It may enhance the effects of general anesthetics to increase the risk of hypotension in surgery.

Clinical Implication: Blood pressure should be closely monitored under anesthesia and anesthetic dosages may need to be titrated.

CNS Depressants (such as barbiturates, benzodiazepines)

Interaction: CNS depression may occur with these drugs. Since phenoxybenzamine lowers blood pressure, the risk of severe hypotension and sedation may be increased when CNS depressants are used concurrently.

Clinical Significance: Use these drugs with caution in combination and should watch the animal for signs of excessive sedation or hypotension._{[14] [15]}

Uses And Administration

Uses

Treatment of Pheochromocytoma:

 Phenoxybenzamine is the most commonly used drug in veterinary medicine for the treatment of pheochromocytoma, a tumor of the adrenal glands that causes an excessive production of catecholamines, such as adrenaline. This condition is characterized by high blood pressure and other symptoms. Phenoxybenzamine controls hypertension by blocking the alpha-adrenergic receptors and preventingvasoconstriction. Phenoxybenzamine can be administered in animals suffering from urinary retention caused by urethral spasm. It does this by blocking the alpha receptors in the smooth muscles of the urethra, relaxing the muscles to make urination easier.
Treatment of Laminitis in Horses:

In horses, phenoxybenzamine is used as part of the treatment for laminitis, which is inflammation of the hooves, especially when it is associated with decreased blood flow to the hoof. The drug can be useful by preventing vasoconstriction and thereby improving blood flow to the affected area.

Bladder and Urethral Relaxation:

Phenoxybenzamine can be used to relax smooth muscle in the bladder and urethra, which may be helpful for conditions such as urinary retention due to dysfunction of the urethral or bladder sphincter.

Vasodilation for Poor Circulation:

 It may be administered to enhance blood flow in animals suffering from peripheral vascular disease or those that have a decreased blood flow. This is less commonly used but is beneficial in some clinical conditions.

Treatment of Urinary Obstruction:

 Phenoxybenzamine is used in urethral obstruction, particularly in male dogs, where the smooth muscle is relaxed and allows the urine to pass through easily.

Important Notes:

Phenoxybenzamine is a strong medication with side effects, which may include hypotension (low blood pressure), tachycardia, and reflex tachycardia. It should therefore be monitored.

It's not a common first-line treatment but should be considered under veterinary guidance in specific cases._{[16] [17]}

Administration:

The specific dosage of phenoxybenzamine will depend on the species being treated, the specific condition, and the severity of the illness. For veterinary use, phenoxybenzamine is usually administered in the following forms:

Oral tablets – These are the most common form used for chronic conditions or outpatient care.

Capsules or solutions – In some cases, liquid formulations may be used.

General dosage guidelines are as follows:

For dogs: The usual dose is between 0.25 to 0.5 mg/kg of body weight, administered 2 to 3 times daily. Dosage can be adjusted based on the animal's response and tolerance.

For cats: The typical dose range is similar, starting at 0.25 mg/kg and adjusting as necessary. For other species: Dosages will vary based on the animal's weight, clinical condition, and veterinary guidance.

Administration Guidelines:

Administration with food: Phenoxybenzamine is usually administered with food to minimize the risk of gastrointestinal side effects, such as nausea and vomiting.

Tapering: The dose should be tapered down gradually when the treatment is to be discontinued to avoid the risk of withdrawal symptoms or abrupt increase in blood pressure. Phenoxybenzamine can be an important veterinary treatment for some conditions. Its use, however is always under the guidance of the veterinarian. They will adjust doses and monitor for side effects to ensure the safety and effectiveness for the individual animal._{[18] [19] [20]}

Adverse Effects and Treatment

The inhibiting action of alpha-adrenoreceptors is the primary cause of phenoxybenzamine's negative effects. These include nasal congestion and miosis, reflex tachycardia, orthostatic hypotension and dizziness, and possible ejaculatory inhibition. Exercise, heat, a large meal, or alcohol consumption can all exacerbate the hypotensive effect. Other side effects include dry mouth and decreased perspiration. These symptoms can be reduced by starting with a low dose and may go away with continuing use.

Overdosing can cause severe hypotension, and therapy involves parenteral fluid volume replacement and postural measures to maintain circulation. Since ana adrenaline also stimulates beta receptors, which results in increased hypotension and tachycardia, sympathomimetics are thought to be of little use. It has been demonstrated that phenoxybenzamine causes cancer in animals and mutagenesis in in vitro experiments._{[21] [22]}

Precautions:

The following precautions of phenoxybenzamine are;

Kidney Function

Renal Impairment: Animals with impaired renal function should be monitored closely, as the drug may alter renal perfusion due to its vasodilatory effect. Dosage adjustments may be required for these animals.

Liver Function

Liver Disease: Phenoxybenzamine is metabolized by the liver, so animals with hepatic insufficiency may have altered drug metabolism. The veterinarian may need to adjust dosing based on liver function.

Gastrointestinal Disturbances

Vomiting and Diarrhea: Some animals may experience gastrointestinal upset, including vomiting and diarrhea. These side effects should be monitored and managed.

Pregnancy and Lactation

Pregnancy Use: Phenoxybenzamine is usually avoided in pregnancy as the developing fetus might be adversely affected. Use this drug in pregnant animals only after consulting a veterinarian.

Lactating Animals: The use of phenoxybenzamine during lactation has not been studied adequately; thus, its use is advised with caution in nursing animals.

Hypersensitivity Reaction

Allergic Reactions: Although these are rare, allergic reactions to phenoxybenzamine do occur. Monitor for allergic signs, such as swelling, hives, or respiratory distress.

Age Considerations

Pediatric and Geriatric Animals: Older animals or animals with weakened systems (because of age or disease) may need adjustment in dosing. Pediatrics (young animals) can also react differently to this medication, so caution should be exercised.

General Monitoring

Clinical Monitoring: Regular veterinary follow-ups are required to monitor the response of the animal to treatment, such as blood pressure, heart rate, and signs of side effects.

Withdrawal: If severe side effects, such as severe hypotension or cardiovascular events, are observed, then the drug needs to be discontinued or the dose needs to be changed.

Prevent Overdose

Overdose Symptoms: Animals may develop symptoms of extreme hypotension, tachycardia, and potentially collapse when an overdose is suspected. Overdose should be reported to the veterinarian for immediate attention.

Liver Disease: Phenoxybenzamine is metabolized by the liver, so animals with hepatic insufficiency may have altered drug metabolism. The veterinarian may need to adjust dosing based on liver function.

Vomiting and Diarrhea: Some animals may experience gastrointestinal upset, including vomiting and diarrhea. These side effects should be monitored and managed._{[23] [24] [25]}

REFERENCES

1. 1. 1. 1. Hadi, M., & Hassan, M. (2007). Phenoxybenzamine Treatment Is Insufficient to Prevent the Stress-induced. International Journal of Pharmacology, 3(2), 195-197., 2007
         2. Hadi, M., & Hassan, M. (2007). Phenoxybenzamine Treatment Is Insufficient to Prevent the Stress-induced. International Journal of Pharmacology, 3(2), 195-197
         3. Maling, H.M., Williams, M.A., Highman, B., Garbus, J. and Hunter, J., 1964. The influence of phenoxybenzamine and isopropylmethoxamine (BW 61-43) on some cardiovascular, metabolic, and histopathologic effects of norepinephrine infusions in dogs. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 248, pp.54-72.
         4. Ledox, gillies  ‘’on the  pharmacology of phenoxybenzamine’’(1960
         5. Woodruff, E. H. "Phenethylamines. IV. Dimethoxy and Dihydroxyphenyl-n-propylamines (?-Methyl-?-phe?ethylamines)." Journal of the American Chemical Society 64.12 (1942): 2859-2862.
         6. Belleau, B. "Mechanism of Drug Action at Receptor Surfaces--II. Chemical Reactivity of N-(?-chloroethyl)-Phenoxyethylamines in Relation to Adrenergic Blocking Activity." Journal of Medicinal Chemistry 1.4 (2002): 327-342.
         7. Anderson, Robert James. "Beta adrenergic blocking agents." (1968).
         8. Nickerson, Mark. "New developments in adrenergic blocking drugs." Annals of the New York Academy of Sciences 139.3 (1967): 571-579.
         9. Nickerson, Mark, and George M. Nomaguchi. "Locus of the adrenergic blocking action of dibenamine." J. Pharmacol. & Exper. Therap. 93 (1948): 40.
         10. Hjort, Axel M., Lowell O. Randall, and EDWIN J. DE BEER. "The Pharmacology of Compounds Related to ?-2, 5-Dimethoxy Phenethyl Amine: I. The Ethyl, Isopropyl and Propyl Derivatives." Journal of Pharmacology and Experimental Therapeutics 92, no. 3 (1948): 283-290.
         11. Kattus, A. A., Ross, G., & Hall, V. E. (Eds.). (1970). Cardiovascular Beta Adrenergic Responses: Proceedings of a Conference Held February 1968 (No. 13). Univ of California Press.
         12. De Marinis, R. M., W. M. Bryan, D. H. Shah, J. P. Hieble, and R. G. Pendleton. ". alpha.-Adrenergic agents. 1. Direct-acting. alpha. 1 agonists related to methoxamine." Journal of Medicinal Chemistry 24, no. 12 (1981): 1432-1437.
         13. Abboud, F.M., 1968. Concepts of adrenergic receptors. Medical Clinics of North America, 52(5), pp.1009-1016.
         14. Marshall, Marion G. "A Study of the Adrenergic Blocking Agent, Dibenamine." University of Western Ontario Medical Journal 19, no. 3 (1949): 102-116.
         15. Dukes, M., and Leslie Harold Smith. ". beta.-Adrenergic blocking agents. 9. Absolute configuration of propranolol and of a number of related aryloxypropanolamines and arylethanolamines." Journal of Medicinal Chemistry 14, no. 4 (1971): 326-328.
         16. Belleau, B. "Relationships between agonists, antagonists and receptor sites." Adrenergic Mechanisms 223 (1960): 244.
         17. Day, M. D. (1962). Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium and xylocholine. British Journal of Pharmacology and Chemotherapy, 18(2), 421-439.
         18. WHEATLEY, WILLIAM B., WILLIAM E. FITZGIBBON Jr, WILLIAM F. MINOR, RICHARD R. SMITH, and LEE C. CHENEY. "Basic Ethers Derived from ?-Hydroxyphenethylamines." The Journal of Organic Chemistry 23, no. 9 (1958): 1360-1363.
         19. Baco, Z. M. (1961). Adrenergic mechanisms:(Ciba Foundation Symposium Jointly with Committee for Symposia on Drug Action). JR Vane, GEW Wolstenholme and Maeve O'Connor,(Editors) 1960. J. and A. Churchill Ltd., London, pp. 632, 70s
         20. IPSON, R. S., & CLAPP, M. A. (1946). NOTE ON SOME AZOMETHINES FROM p-DIALKYLAMINOBENZALDEHYDES. The Journal of Organic Chemistry, 11(3), 292-295.
         21. Hetrick, Peter, and Elizabeth Davidow. "Diversity in veterinary medicine." Can J Vet Res 67 (2003): 30-38.
         22. Sear, John W. "Antihypertensive drugs and vasodilators." In Pharmacology and Physiology for Anesthesia, pp. 535-555. Elsevier, 2019.
         23. Elliott, Jonathan, and Ludovic Pelligand. "Pharmacology of antihypertensive drugs." Hypertension in the Dog and Cat (2020): 267-313.
         24. Cooke, Kirsten L., and Patti S. Snyder. "Calcium channel blockers in veterinary medicine." Journal of Veterinary Internal Medicine 12, no. 3 (1998): 123-131.
         25. Spencer, S. (2020). Management of Hypertension in Dogs. Hypertension in the Dog and Cat, 331-367.